Skip links

About us

OncoOne: A key player in shaping the future of medicine

Fighting Chronic Inflammatory Diseases and Cancer with Precision!

OncoOne’s mission is to discover and deliver targeted medicines and solutions that address chronic inflammatory diseases and cancer to improve patient outcomes and quality of life effectively.

We Create Precision Medicines That Make a Real Difference for Patients

At OncoOne, our world-class team of antibody engineers specializes in developing and fine-tuning unique monoclonal antibodies, customized for complex and novel targets as well as specific therapeutic requirements. Our groundbreaking discovery of oxMIF, a disease-associated isoform of the macrophage migration inhibitory factor (MIF), ensures the precise delivery of our innovative medicines to effectively address chronic inflammatory diseases and cancer. By leveraging collaborations with leading experts and cutting-edge technologies like AI and in-depth data analysis, we strive to revolutionize standard-of-care treatments for underserved patient populations where substantial medical needs persist. Our aim is to deliver innovative treatments with unmatched safety and efficacy, surpassing mere symptom relief and making significant contributions to a healthier global community.

“Our vision runs deep, and our path is clear. We're fully committed to making a meaningful difference in people's lives through the innovative precision medicines we create together. It's our team's dedication to innovation and inclusivity, coupled with unwavering integrity, that drives every aspect of our work.”
- Randolf Kerschbaumer, CEO
Photo of the founders of OncoOne

Randolf Kerschbaumer, PhD

Co-Founder & Chief Executive Officer

Michael Thiele, PhD

Co-Founder & Chief Scientific Officer

Alexander Schinagl, PhD

Co-Founder & Chief Technology Officer

Founders

Our founders, Randolf Kerschbaumer, Michael Thiele, and Alexander Schinagl, are the pioneers behind the novel therapeutic target oxMIF, playing a crucial role in shaping the future of medicine. As experts in antibody engineering, we endeavor to provide innovative treatments with the potential to alter the course of the disease, focusing on improving patients' quality of life rather than just managing symptoms.

Leadership

Leadership Team

Randolf Kerschbaumer, PhD

Randolf Kerschbaumer, PhD

Co-Founder & Chief Executive Officer
Michael Thiele, PhD

Michael Thiele, PhD

Co-Founder & Chief Scientific Officer
Alexander Schinagl, PhD

Alexander Schinagl, PhD

Co-Founder & Chief Technology Officer
Photo of Christine Landlinger-Schubert, PhD

Christine Landlinger-Schubert, PhD

Vice President Preclinical and Translational R&D
Friedmund Bachmann

Friedmund Bachmann

Vice President CMC
Maria Reitzinger, BA

Maria Reitzinger, BA

Head of Finance and Administration

Scientific Advisory Board

Prof. Michael Freissmuth, M.D.

Prof. Michael Freissmuth, MD

Medical University Vienna, AT
Prof. Dirk Jäger, M.D.

Prof. Dirk Jäger, MD

National Center for Tumor Diseases (NCT) Heidelberg, DE

Prof. em. Florian Rüker, PhD

University of Natural Resources and Life Sciences, AT
Prof. Seamas Donnelly, M.D.

Prof. Seamas Donnelly, MD

Trinity College Dublin, IRE
Prof. Jennifer Guerriero, Ph.D. Assistant Professor, Harvard Medical School and Director of the Breast Tumor lmmunology Laboratory at the Dana Farber Cancer Institute.

Prof. Jennifer Guerriero, PhD

Harvard Medical School, US
Prof. Robert A. Mitchell, M.D.

Prof. Robert A. Mitchell, MD

University of Louisville, US

Clinical Advisory Board

Prof. Michael Freissmuth, M.D.

Prof. Michael Freissmuth, MD

Medical University Vienna, AT
Prof. Seamas Donnelly, M.D.

Prof. Seamas Donnelly, MD

Trinity College Dublin, IRE

Prof. Richard Bucala, MD, PhD

Yale School of Medicine, US

Prof. Daniel Aletaha, MD

Medical University Vienna, AT

Our team is highly committed to our shared goal of developing breakthrough cancer therapeutics.

Collaborating

We aim to partner with outstanding collaborators to propel pioneering treatments forward through flexible scientific approaches, swiftly bringing precision medicines to those in need. Our goal is to have top talent engaged in cutting-edge research, necessitating the identification and cultivation of exceptional partnerships. If you are interested in partnering with us, please fill out our contact form.

Our Current Partners

Professor Nicoletti, affiliated with the University of Catania, is a prominent authority in MIF research, recognized worldwide for expertise in preclinical models related to immunoinflammatory/autoimmune diseases and cancer. Leveraging a robust background in developing in vivo animal models of inflammation, our collaboration with Professor Nicoletti's team will delve into exploring the anti-inflammatory potential of OncoOne’s anti-oxMIF antibodies in arthritis and colitis models.

Professor Tam's research at Imperial College London delves into the role of cytokines in glomerulonephritis, diabetic nephropathy, and renal allograft rejection. Together with his team, he pioneers experimental therapies for glomerulonephritis, employing innovative approaches like soluble cytokine receptors, antagonists, and monoclonal antibodies. Leveraging their expertise, they closely collaborate with OncoOne to exploring the therapeutic efficacy of anti-oxMIF antibodies in experimental glomerulonephritis.

Brown University Logo
Brown University

GenScript ProBio, a premier global CDMO, accelerates the drug development journey from discovery to commercialization with its holistic solutions and efficient biologic processes. Their integrated DNA to GMP platform includes cell line development, commercial licensing, and both process and analytical development, leading up to clinical and commercial manufacturing. In November 2021, OncoOne partnered with GenScript ProBio to produce our monoclonal antibodies targeting oxMIF

 

Read more with our Press Releases 

Adgyl Life Science provides comprehensive services for Discovery, Preclinical, and Early Clinical development programs, ensuring safety assessment and global regulatory compliance. With over 30 years of GLP experience, Adgyl guarantees the highest data quality and reliability. They are our trusted partner for pharmacokinetic and toxicology studies, advancing our therapeutic monoclonal antibodies to clinical trials.

OncoOne Partners worldwide

GenScript ProBio United States

Brown University

Rhode Island, USA

GenScript ProBio

Rijswijk, Netherlands

OncoOne Headquarters

Vienna & Lower Austria, Austria

GenScript ProBio China

Imperial College London

London, UK

University of Catania

Sicily, Italy

Adgyl Lifesciences

Bangalore, India

collaborations

Investing in precision medicines

OncoOne is seeking investors for a Series A+ / B financing and is looking for strategic partnerships to propel the development of its pipeline.

We're open to discussing various investment approaches, including the option to fund our platforms/assets separately.

OncoOne welcomes offers from strategic partners for a global licensing transaction, strategic alliance or build-to-buy.

OncoOne generates novel and highly potent antibody modalities targeting oxMIF to treat underserved patient populations living with solid cancers and/or chronic inflammatory diseases.

Collaborating with OncoOne can take many forms:

  • Joint Research and Development (R&D)
  • Data Sharing and Analysis
  • Licensing and Commercialization

Just to name a few.

Be at the forefront of tomorrow: Invest in breakthrough science and innovation with OncoOne.

We are shaping the future:

  • Pioneering cutting-edge technologies: Join us in revolutionizing industries and tackling global challenges.

  • High-growth potential: Invest in a company poised for exponential growth and significant returns.

  • Long-term impact: Be part of something bigger - contribute to positive societal change through groundbreaking advancements.

Home